Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai Inc.

WOODCLIFF LAKE, N.J., Dec. 1, 2016 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Rebecca Jolley as Senior Vice President Americas Commercial, Oncology Business Group. Ms. Jolley will lead Eisai's Americas Oncology Commercial team in creating and driving commercial strategies for the company's approved products, pipeline assets and late-stage compounds approaching the commercialization stage. In addition to her functional responsibilities, she will serve as a member of the Eisai Inc. Executive Committee.  

Rebecca Jolley

"Our objective is to provide the very best customer service in the industry with an unrivaled passion for patients," said Gary Hendler, Chief Commercial Officer of Eisai's Oncology Business Group. "Rebecca has had tremendous success in launching oncology brands, developing and collaborating on disease awareness initiatives, implementing return-to-growth strategies, and leading large cross-functional teams in working together to deliver high quality value to customers and patients. We are confident that Rebecca's extensive experience and proven leadership will help drive the growth of Eisai's oncology business in the Americas, and ensure that all appropriate on label patients have rapid and sustained access to our innovative cancer medicines." 

Ms. Jolley joins Eisai from Novartis, where she spent 24 years in a variety of increasingly responsible roles, including sales, market access, marketing, brand leadership and general management. She started her career with Novartis in the UK, then transferred to the U.S. to join Novartis Oncology. During her tenure, she held a number of executive leadership roles that included Vice President, Oncology General Manager for Australia and New Zealand; Vice President, US Oncology Marketing; Vice President, Global Disease Leader Chronic Myeloid Leukemia; and Vice President and Head, Cardiovascular & Respiratory Business Unit.  

Ms. Jolley is a graduate of Lancaster University in England, where she holds a BSc Honors First Class in Geography and Biological Sciences. She has been a member of the Healthcare Businesswomen's Association (HBA) since 2005.

Eisai Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at

Eisai Co. Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology. For more information about Eisai Co., Ltd., please visit

Media Inquiries                     

Investor Inquiries              

Patti Councill                            

Ivor Macleod

Eisai Inc.                                 

Eisai Inc.




Photo -

SOURCE Eisai Inc.

Type Press Release

Date Released December 01, 2016

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields